Department of Gynecology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, China.
Int J Gynecol Pathol. 2010 Nov;29(6):587-93. doi: 10.1097/PGP.0b013e3181e0898e.
Lysosome-associated protein transmembrane 4β-35 (LAPTM4B-35) is a member of the mammalian 4-tetratransmembrane spanning protein superfamily, which is overexpressed in several solid malignancies. However, the expression of LAPTM4B-35 and its role in the progression of cervical carcinoma is unknown. The aim of this study was to determine the level of expression of LAPTM4B-35 in cervical carcinoma. Immunohistochemistry was used to determine the expression of LAPTM4B-35 protein in 53 cervical intraepithelial neoplasias (CINs) and 113 cervical carcinomas in comparison with 20 normal cervical specimens. The correlation between the expression of the LAPTM4B-35 protein and the clinicopathologic characteristics of patients with cervical carcinoma was analyzed. Statistical analysis showed that LAPTM4B-35 expression was significantly elevated in CINII/III and cervical carcinoma but not in CINI compared with the normal controls (P=0.002, P<0.001 and P=0.289, respectively). In addition, the LAPTM4B-35 expression was significantly higher in both the CINII/III and cervical carcinoma cases than in the CINI cases (P=0.021 and P=0.002, respectively). High LAPTM4B-35 staining was present in 72.57% (82 of 113) of all the cases with cervical carcinoma. The overexpression of LAPTM4B-35 was significantly associated with the International Federation of Gynecology and Obstetrics stage (P=0.014), tumor histologic grade (P=0.033), lymph node metastasis (P=0.045), and recurrence (P=0.010). The Kaplan-Meier survival analysis showed that the high expression of LAPTM4B-35 was related to the poor overall survival and disease-free survival of patients with cervical carcinoma (P=0.004 and P=0.005, respectively). Multivariate Cox analysis showed that LAPTM4B-35 was an independent factor for both overall survival and disease-free survival (P=0.015 and P=0.016, respectively). Overexpression of LAPTM4B-35 may be associated with tumor progression in cervical carcinoma and thus may serve as a new molecular marker to predict the prognosis of cervical carcinoma patients.
溶酶体相关蛋白跨膜 4β-35（LAPTM4B-35）是哺乳动物 4 次跨膜蛋白超家族的成员，在几种实体恶性肿瘤中过表达。然而，LAPTM4B-35 的表达及其在宫颈癌进展中的作用尚不清楚。本研究旨在确定 LAPTM4B-35 在宫颈癌中的表达水平。免疫组织化学法检测 53 例宫颈上皮内瘤变（CIN）和 113 例宫颈癌与 20 例正常宫颈标本中 LAPTM4B-35 蛋白的表达。分析 LAPTM4B-35 蛋白的表达与宫颈癌患者临床病理特征的相关性。统计学分析显示，与正常对照组相比，LAPTM4B-35 在 CINII/III 和宫颈癌中表达显著升高（P=0.002，P<0.001 和 P=0.289）。此外，LAPTM4B-35 在 CINII/III 和宫颈癌病例中的表达均显著高于 CINI 病例（P=0.021 和 P=0.002）。在所有宫颈癌病例中，72.57%（82/113）的病例存在 LAPTM4B-35 高染色。LAPTM4B-35 的过表达与国际妇产科联合会（FIGO）分期（P=0.014）、肿瘤组织学分级（P=0.033）、淋巴结转移（P=0.045）和复发（P=0.010）显著相关。Kaplan-Meier 生存分析显示，LAPTM4B-35 高表达与宫颈癌患者总生存和无病生存不良相关（P=0.004 和 P=0.005）。多变量 Cox 分析显示，LAPTM4B-35 是总生存和无病生存的独立因素（P=0.015 和 P=0.016）。LAPTM4B-35 的过表达可能与宫颈癌的肿瘤进展有关，因此可能成为预测宫颈癌患者预后的新分子标志物。
